Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xigris Best-Case Label Would Be 400,000 Patients; User Fee Date Is Oct. 27

Executive Summary

Lilly is hoping to receive Xigris labeling permitting use in approximately 400,000 severe sepsis patients per year.
Advertisement

Related Content

Lilly Xigris Phase IV Studies Will Enroll 14,000 Sepsis Patients
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
Lilly Xigris Phase IV Studies Will Enroll 14,000 Sepsis Patients
Lilly Xigris Indication For Low-Risk Sepsis Could Require Large Study
Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients
Lilly Xigris Indication For Low-Risk Sepsis Could Require Large Study
FDA Xigris Efficacy Analysis Suggests APACHE II Test Can Guide Therapy
FDA Xigris Efficacy Analysis Suggests APACHE II Test Can Guide Therapy
Advertisement
UsernamePublicRestriction

Register

PS038724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel